 "Jubilant signs long-term supply contracts for radiopharmaceuticals in US")
Jubilant DraxImage Inc (JDI), the Montreal (Canada) based wholly-owned subsidiary of the Noida-based Jubilant Pharma, has signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans. JDI will supply these products over a period of 39 months effective from January 2017.
Jubilant DraxImage is a nuclear medicine company that develops, manufactures and commercialises radiopharmaceuticals used for the diagnosis, treatment and monitoring of disease.
“We are delighted to announce signing of long term contracts by our Jubilant Draximage business where we are the leader in some of the key products in the US market. These contracts provide visibility on our future revenues with the differentiated and niche products in our Specialty Pharma business and will strengthen the company for its growth, going forward,” said Shyam Bhartia, chairman and Hari Bhartia, co-chairman and MD, Jubilant Life Sciences Limited, in a joint statement. Jubilant Pharma Limited is a wholly-owned subsidiary of Jubilant Life Sciences Ltd, an integrated global pharmaceuticals and life sciences company.
Jubilant Pharma’s radiopharmaceuticals business develops, manufactures and markets a portfolio of products that enable nuclear medicine physicians to deliver personalised healthcare to their patients around the globe. Its core products primarily serve patients with cardiac, thyroid and lung disease providing reliable high quality imaging agents and patient specific therapies for nuclear medicine procedures.
The US market accounts for approximately 70 percent of the radiopharmaceuticals business’ sales, with Canada accounting for close to 20 percent sales and the rest of the revenues coming from markets in Europe, Latin America and Asia.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%